{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:55:23Z","timestamp":1778781323043,"version":"3.51.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,2,24]],"date-time":"2016-02-24T00:00:00Z","timestamp":1456272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan (US)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s00417-016-3299-9","type":"journal-article","created":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T21:48:34Z","timestamp":1456264114000},"page":"1151-1158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial"],"prefix":"10.1007","volume":"254","author":[{"given":"Ingeborg","family":"Stalmans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Oddone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Francesca","family":"Cordeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Hommer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Montesano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordana","family":"Sunaric-M\u00e9gevand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,24]]},"reference":[{"key":"3299_CR1","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.ophtha.2008.02.005","volume":"115","author":"A Heijl","year":"2008","unstructured":"Heijl A, Bengtsson B, Chauhan BC, Lieberman MF, Cunliffe I, Hyman L, Leske MC (2008) A comparison of visual field progression criteria of 3 major glaucoma trials in early manifest glaucoma trial patients. Ophthalmology 115:1557\u20131565. doi: 10.1016\/j.ophtha.2008.02.005","journal-title":"Ophthalmology"},{"key":"3299_CR2","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1167\/iovs.02-0543","volume":"44","author":"BW Gillespie","year":"2003","unstructured":"Gillespie BW, Musch DC, Guire KE, Mills RP, Lichter PR, Janz NK, Wren PA, CIGTS (Collaborative Initial Glaucoma Treatment Study) Study Group (2003) The collaborative initial glaucoma treatment study: Baseline visual field and test-retest variability. Invest Ophthalmol Vis Sci 44:2613\u20132620","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3299_CR3","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ophtha.2012.09.005","volume":"120","author":"PJ Ernest","year":"2013","unstructured":"Ernest PJ, Schouten JS, Beckers HJ, Hendrikse F, Prins MH, Webers CA (2013) An evidence-based review of prognostic factors for glaucomatous visual field progression. Ophthalmology 120:512\u2013519. doi: 10.1016\/j.ophtha.2012.09.005","journal-title":"Ophthalmology"},{"key":"3299_CR4","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/archopht.126.8.1030","volume":"126","author":"BC Chauhan","year":"2008","unstructured":"Chauhan BC, Mikelberg FS, Balaszi AG, LeBlanc RP, Lesk MR, Trope GE Canadian Glaucoma Study Group; (2008) Canadian Glaucoma Study: 2. Risk factors for the progression of open-angle glaucoma. Arch Ophthalmol 126:1030\u20131036. doi: 10.1001\/archopht.126.8.1030","journal-title":"Arch Ophthalmol"},{"key":"3299_CR5","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","volume":"385","author":"DF Garway-Heath","year":"2015","unstructured":"Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, Azuara-Blanco A, Bourne RR, Broadway DC, Cunliffe IA, Diamond JP, Fraser SG, Ho TA, Martin KR, McNaught AI, Negi A, Patel K, Russell RA, Shah A, Spry PG, Suzuki K, White ET, Wormald RP, Xing W, Zeyen TG (2015) Latanoprost for open-angle glaucoma (UKGTS): A randomised, multicentre, placebo-controlled trial. Lancet 385:1295\u20131304. doi: 10.1016\/S0140-6736(14)62111-5","journal-title":"Lancet"},{"key":"3299_CR6","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ophtha.2005.01.042","volume":"112","author":"R Valk van der","year":"2005","unstructured":"van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH (2005) Intraocular pressure-lowering effects of all commonly used glaucoma drugs: A meta-analysis of randomized clinical trials. Ophthalmology 112:1177\u20131185","journal-title":"Ophthalmology"},{"key":"3299_CR7","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/IJG.0b013e3181666557","volume":"17","author":"F Aptel","year":"2008","unstructured":"Aptel F, Cucherat M, Denis P (2008) Efficacy and tolerability of prostaglandin analogs: A meta-analysis of randomized controlled clinical trials. J Glaucoma 17:667\u2013673. doi: 10.1097\/IJG.0b013e3181666557","journal-title":"J Glaucoma"},{"key":"3299_CR8","doi-asserted-by":"crossref","first-page":"518","DOI":"10.5301\/ejo.5000270","volume":"23","author":"I Stalmans","year":"2013","unstructured":"Stalmans I, Sunaric M\u00e9gevand G, Cordeiro MF, Hommer A, Rossetti L, Go\u00f1i F, Heijl A, Bron A (2013) Preservative-free treatment in glaucoma: Who, when, and why. Eur J Ophthalmol 23:518\u2013525. doi: 10.5301\/ejo.5000270","journal-title":"Eur J Ophthalmol"},{"key":"3299_CR9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/bjophthalmol-2012-303040","volume":"97","author":"DG Day","year":"2013","unstructured":"Day DG, Walters TR, Schwartz GF, Mundorf TK, Liu C, Schiffman RM, Bejanian M (2013) Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: A 12-week, randomised, double-masked trial. Br J Ophthalmol 97:989\u2013993. doi: 10.1136\/bjophthalmol-2012-303040","journal-title":"Br J Ophthalmol"},{"key":"3299_CR10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/bjophthalmol-2012-302121","volume":"97","author":"JF Rouland","year":"2013","unstructured":"Rouland JF, Traverso CE, Stalmans I, Fekih LE, Delval L, Renault D, Baudouin C, T2345 Study Group (2013) Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol 97:196\u2013200. doi: 10.1136\/bjophthalmol-2012-302121","journal-title":"Br J Ophthalmol"},{"key":"3299_CR11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40261-014-0203-4","volume":"34","author":"M Sanford","year":"2014","unstructured":"Sanford M (2014) Preservative-free latanoprost eye drops in patients with primary open-angle glaucoma\/ocular hypertension. Clin Drug Investig 34:521\u2013528. doi: 10.1007\/s40261-014-0203-4","journal-title":"Clin Drug Investig"},{"key":"3299_CR12","volume-title":"Terminology and guidelines for glaucoma","author":"European Glaucoma Society","year":"2014","unstructured":"European Glaucoma Society (2014) Terminology and guidelines for glaucoma, 4th edn. Editrice Publicomm s.r.l, Savona","edition":"4"},{"key":"3299_CR13","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0002-9394(03)00098-9","volume":"135","author":"RK Parrish","year":"2003","unstructured":"Parrish RK, Palmberg P, Sheu WP, XLT Study Group (2003) A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 135:688\u2013703","journal-title":"Am J Ophthalmol"},{"key":"3299_CR14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0002-9394(02)01827-5","volume":"135","author":"RS Noecker","year":"2003","unstructured":"Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM, Bimatoprost\/Latanoprost Study Group (2003) A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 135:55\u201363","journal-title":"Am J Ophthalmol"},{"key":"3299_CR15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/BF02850299","volume":"18","author":"S Gandolfi","year":"2001","unstructured":"Gandolfi S, Simmons ST, Sturm R, Chen K, VanDenburgh AM, Bimatoprost Study Group 3 (2001) Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 18:110\u2013121","journal-title":"Adv Ther"},{"key":"3299_CR16","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2147\/OPTH.S84163","volume":"9","author":"MF Cordeiro","year":"2015","unstructured":"Cordeiro MF, Goldberg I, Schiffman R, Bernstein P, Bejanian M (2015) Efficacy of a preservative-free formulation of fixed-combination bimatoprost and timolol (Ganfort PF) in treatment-na\u00efve patients vs previously treated patients. Clin Ophthalmol 9:1605\u20131611","journal-title":"Clin Ophthalmol"},{"key":"3299_CR17","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/archophthalmol.2010.196","volume":"128","author":"BC Chauhan","year":"2010","unstructured":"Chauhan BC, Mikelberg FS, Artes PH, Balazsi AG, LeBlanc RP, Lesk MR, Nicolela MT, Trope GE, Canadian Glaucoma Study Group (2010) Canadian Glaucoma Study: 3 impact of risk factors and intraocular pressure reduction on the rates of visual field change. Arch Ophthalmol 128:1249\u20131255. doi: 10.1001\/archophthalmol.2010.196","journal-title":"Arch Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-016-3299-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-016-3299-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-016-3299-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:40:58Z","timestamp":1559058058000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-016-3299-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,24]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["3299"],"URL":"https:\/\/doi.org\/10.1007\/s00417-016-3299-9","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,24]]}}}